🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Beijing Continent Pharmaceutical clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Beijing Continent Pharmaceutical as lead sponsor. Synced 26 Sep 2026
7Current trials
6Recruiting now
2Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Beijing Continent Pharmaceutical is the lead sponsor of 7 current clinical trials in our China register. 6 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Hydronidone and Pirfenidone. The most-studied condition is Liver Fibrosis.

ClinicalTrials.gov trials by status

  • Recruiting686%
  • Not yet open114%

Trials by phase

  • Phase 3343%
  • Phase 1229%
  • Phase 2/3114%
  • Phase 2114%
01

Clinical trials sponsored by Beijing Continent Pharmaceutical

7 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis
NCT05905172 · ClinicalTrials.gov ↗ · Liver Fibrosis
Phase 3 Recruiting 2023-08 China
Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis
NCT05288179 · ClinicalTrials.gov ↗ · Pneumoconiosis
Phase 3 Recruiting 2022-06 China
Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia
NCT07388680 · ClinicalTrials.gov ↗ · Radiation-induced Lung Injury, Immune-related Pneumonia
Phase 2/3 Recruiting 2026-03 China
A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency
NCT07262333 · ClinicalTrials.gov ↗ · Renal Insufficiency Chronic
Phase 1 Recruiting 2025-12 China
F573 for Injection for the Treatment of Liver Injury/Failure
NCT05689645 · ClinicalTrials.gov ↗ · Acute Liver Failure, Acute-On-Chronic Liver Failure
Phase 2 Recruiting 2023-03 China
Preliminary Human Trials of F230 Tablets
NCT06899815 · ClinicalTrials.gov ↗ · Pulmonary Hypertension
Phase 1 Recruiting 2025-05 China
A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.
NCT07412236 · ClinicalTrials.gov ↗ · Liver Fibrosis, Liver Fibrosis in Chronic Hepatitis B
Phase 3 Not yet open 2026-01 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Beijing Continent Pharmaceutical trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Beijing Continent Pharmaceutical trials

9 conditions
Liver Fibrosis2Pneumoconiosis1Radiation-induced Lung Injury1Immune-related Pneumonia1Liver Fibrosis in Chronic Hepatitis B1Renal Insufficiency Chronic1Acute Liver Failure1Acute-On-Chronic Liver Failure1Pulmonary Hypertension1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China76

A trial with sites in more than one country appears in each of those registers.

05

Questions about Beijing Continent Pharmaceutical trials

How many clinical trials does Beijing Continent Pharmaceutical sponsor?

Beijing Continent Pharmaceutical is the lead sponsor of 7 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Beijing Continent Pharmaceutical trials recruiting?

Yes. 6 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Beijing Continent Pharmaceutical testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are Hydronidone (3) and Pirfenidone (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.